AstraZeneca’s IL‑33 biologic Tozorakimab hits multiple Phase III successes – Meet them this September

Altesa BioSciences advances Vapendavir for rhinovirus‑triggered COPD exacerbations

GSK expands its COPD pipeline with a novel siRNA therapy (EMP‑012)

Emerging COPD treatments highlight biologics, bronchoscopic procedures & stem‑cell approaches

ReAlta’s pegtarazimod showing early promise for acute COPD exacerbations in phase 2

GSK’s Nucala gains UK backing, expanding COPD biologic access with NICE recommendation

Windward Bio and Harbour Biomed announce first Phase II dosing in SIRIUS trial for novel COPD antibody therapy

TidalSense secured $19 million to commercialise its AI-powered COPD diagnostic technology

Restoring Antiviral Defence With Interferon Lambda to Prevent Virus Driven Respiratory Exacerbations

11:00 am - Tuesday 15th September 2026

How inhaled mRNA delivery of interferon lambda restores epithelial host resistance to reduce virus driven exacerbations in chronic lung disease
Why targeting interferon lambda upstream of inflammation offers a new preventative strategy beyond bronchodilators biologics and steroids
What early clinical data show including phase 2a asthma results demonstrating safety, target engagement and the potential to translate this approach into COPD

Carsten Rudolph

Managing Director & Chief Executive Officer

Ethris GmbH